CYP2C metabolism of oral antidiabetic drugs - Impact on pharmacokinetics, drug interactions and pharmacogenetic aspects

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 12, 2012, Pages 1549-1563

  Holstein, Andreas ^a   Beil, Winfried ^b   Kovacs, Peter ^c  

^a Lippe Detmold Hospital   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Antidiabetic oral drugs; CYP2C; Drug metabolism; Meglitinides; Pharmacogenetics; Pharmacokinetics; Sulfonylureas; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; CYTOCHROME P450 2C; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG METABOLIZING ENZYME; GEMFIBROZIL; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; LINAGLIPTIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TOLBUTAMIDE; UNINDEXED DRUG; VILDAGLIPTIN;

DRUG EFFECT; ENZYME INHIBITION; ETHNICITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; REVIEW; RISK ASSESSMENT;

ADMINISTRATION, ORAL; BENZAMIDES; BLOOD GLUCOSE; CARBAMATES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GEMFIBROZIL; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

SUS;

EID: 84869400832     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.722619     Document Type: Review

References (120)

1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46
2. International Diabetes Federation. Diabetes Atlas, Fifth Edition. 2011. IDF website. Available from: http://www.idf.org
3. Gaede P, Lund-Andersen H, Parving H-L, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91
4. Scheen AJ. Cytochrome P450 mediated cardiovascular drug interactions. Expert Opin Drug Metab Toxicol 2011;7:1065-82
5. Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-12
6. Preissner S, Kroll K, Dunkel M, et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2010;38(Database issue):D237-43
7. Human Cytochrome P450 Allele Nomenclature Committee. Available from: http://www.imm.ki.se/CYPalleles
8. Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol 2009;5:225-41
9. DiStefano J, Watanabe RM. Pharmacogenetics of anti-diabetes drugs. Pharmaceuticals (Basel) 2010;3:2610-46
10. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011;12:1161-91
11. Sun H, Scott DO. Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics. Chem Biol Interact 2011;194:159-67
12. Tornio A, Niemi M, Neuvonen PJ, et al. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci 2012;33:312-22
13. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96
14. Bennett W L, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;155:67-78
15. Anderson SL, Marrs JC. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother 2012;46:590-8
16. McGraw J, Waller M. Cytochrome P450 variations in different ethnic populations. Exp Opin Drug Metab Toxicol 2012;8:371-82
17. Xu H, Murray M, McLachlan AJ. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. Curr Drug Metab 2009;10:643-58
18. Holstein A, Hahn M, Patzer O, et al. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycaemia. Eur J Clin Pharmacol 2011;67:471-6
19. Garcia-Martin E, Martinez C, Ladero JM, et al. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10:29-40
20. Sehra D, Sehra S, Sehra TS. Sulfonylureas: do we need to introspect safety again? Expert Opin Drug Saf 2011;10:851-61
21. Pantalone KM, Kattan MW, Yu C, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 2012; Epub ahead of print
22. Zoungas S, Patel A, Chalmers J, et al. ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-18
23. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
24. Lang V, Youssef N, Light PE. The molecular genetics of sulfonylurea receptors in the pathogenesis and treatment of insulin secretory disorders and type 2 diabetes. Curr Diab Rep 2011;11:543-51
25. Abdelmoneim AS, Hasenbank SE, Seubert JM, et al. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab 2012;14:130-8
26. Müller G, Hartz D, Punter J, et al. Differential interaction of glimepiride and glibenclamide with the ß-cell-sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994;1191:267-77
27. Kramer W, Müller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res 1996;28:464-8
28. Tirkkonen T, Heikkilä P, Huupponen R, et al. Potential CYP29-mediated drug-drug interactions in hospitalized type 2 diabetic patients treated with the sulfonylureas glibenclamide, glimepiride or glipizide. J Intern Med 2010;268:359-66
29. Schelleman H, Bilker WB, Brensinger CM, et al. Anti-infectives and the risk of severe hypoglycemia in glipizide or glyburide. Clin Pharmacol Ther 2010;88:214-22
30. Xu H, Williams WS, Murray M, et al. Effect of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclzide. Brit J Pharmacol 2008;153:1579-86
31. Kihara Y, Otsuki M. Interaction of gliclazide and rifampicin. Diabetes Care 2000;23:1204-5
32. Zhou L, Naraharisetti SB, Liu L, et al. Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos 2010;31:228-42
33. Rydberg T, J€onsson A, Roder M, et al. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994;17:1026-30
34. Kirchheiner J, Bauer S, Meineke I, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002;12:101-9
35. Kirchheiner J, Brockm€oller J, Meineke I, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002;71:286-96
36. Niemi M, Cascorbi I, Timm et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002;72:326-32
37. Wang R, Chen K, Wen S.Y, et al. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin Pharmacol Ther 2005;78:9092
38. Suzuki K, Yanagawa T, Shibasaki T, et al. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 2006;72:148-54
39. Becker ML, Visser LE, Trienekens PH, et al. Cytochrome P450 2C9*2 and*3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2008;83:288-92
40. Surendiran A, Pradhan SC, Agrawal A, et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol 2011;67:797-801
41. Elliot DJ, Suharjono Lewis BC, et al. Identification of the human cytochromes P450 catalysing the ratelimiting pathways of gliclazide elimination. Br J Clin Pharmacol 2007;64:450-7
42. Shao H, Ren XM, Liu NF, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. J Clin Pharm Ther 2010;35:351-60
43. Zhou K, Donnelly N, Burch L, et al. Loss of function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS Study. Clin Pharmacol Ther 2010;87:52-6
44. Zhang Y, Si D, Chen X, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol 2007;64:67-74
45. Kirchheiner J, Roots I, Goldammer M, et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokin 2005;44:1209-25
46. Tan B, Zhang YF, Chen XY, et al. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. Eur J Clin Pharmacol 2010;66:145-51
47. Holstein A, Egberts E-H. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003;111:405-14
48. Holstein A, Patzer O, Machalke K, et al. Substantial increase in incidence of severe hypoglycemia between 1997-2000 and 2007-2010. A German longitudinal population-based study. Diabetes Care 2012;35:972-5
49. Holstein A, Hammer C, Hahn M, et al. Severe sulphonylurea-induced hypoglycaemia-a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 2010;9:675-81
50. Greco D, Oisciotta M, Gambina F, et al. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diabetes 2010;118:215-19
51. Schejter YD, Turvall E, Ackerman Z. Characteristics of patients with sulphonurea-induced hypoglycemia. J Am Med Dir Assoc 2012;13:234-8
52. Holstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 2005;59:103-6
53. Ragia G, Petridis I, Tavridou A, et al. Presence of CYP2C9*3 allele increases risk for hypoglycaemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009;10:1781-7
54. G€okalp O, Gunes A, Cam H, et al. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. Eur J Clin Pharmacol 2011;67:1223-9
55. Kristiansen SB, Løfgren B, Nielsen JM, et al. Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes. Diabetologia 2011;54:451-8
56. Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:744-55
57. NAVIGATOR Study Group. Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-77
58. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32:1900-8
59. Novonorm prescribing information. Novo Nordisk Inc.;2012
60. Starlix prescribing information. Novartis; 2012
61. Pacanowski MA, Hopley CW, Aquilante CL. Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin Drug Metab Toxicol 2008;4:529-44
62. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157-81
63. Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007;46:93-108
64. Niemi M, Leathart JB, Neuvonen PJ, et al. Polymorphism in CYP2C8 is associated with reduced plasma concentration of repaglinide. Clin Pharmacol Ther 2003;74:380-7
65. Kirchheiner J, Meineke I, Müller G, et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in healthy volunteers. Clin Pharmacokinet 2004;43:267-78
66. Kalliokoski A, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol 2010;107:775-81
67. Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005;78:388-99
68. Niemi M, Backmann JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially harzadous interaction between gemfibrozil and repaglinide. Diabetologia 2003;46:347-51
69. Honkalammi J, Niemi M, Neuvonen PJ, et al. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin Pharmacol Ther 2012;doi; 10.1038/clpt.2011.313; [Epub ahead of print]
70. Honkalammi J, Niemi M, Neuvonen PJ, et al. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos 2011;39:1977-86
71. EMEA/11700/03, 21 May 2003. Available from: http://www.emea.eu.int
72. Kajosaari LI, Jaakkola T, Neuvonen PJ, et al. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 2006;62:217-23
73. Kajosaari LI, Backman JT, Neuvonen M, et al. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol 2004;58:390-6
74. Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003;43:649-60
75. Niemi M, Neuvonen PJ, Kivist€o KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. J Clin Pharmacol 2001;70:58-65
76. Busk Bidstrup T, Damkier P, Kristensen Olsen A, et al. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. Br J Clin Pharmacol 2006;61:49-57
77. Niemi M, Kajosaari LI, Neuvonen M, et al. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2004;57:441-7
78. Niemi M, Backman JT, Juntti-Patinen L, et al. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol 2005;60:208-17
79. Takanohashi T, Koizumi T, Mihara R, et al. Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies. Drug Metab Pharmacokinet 2007;22:409-18
80. Hirshberg Y, Karara AH, Pietri AO, et al. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000;23:349-53
81. Anderson D, Shelley S, Crick N, et al. A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers. Int J Clin Pharmacol Ther 2002;42:457-64
82. Anderson D, Shelley S, Crick N, et al. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol 2002;42:1358-65
83. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
84. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007;30:2148-53
85. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-9
86. Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55:1953-62
87. Jaakkola T, Laitila J, Neuvonen PJ, et al. Pioglitazone is metabolized by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006;99:44-51
88. Budde K, Neumayer HH, Fritsche L, et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003;55:368-74
89. Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer in humans. Drug Metab Dispos 2000;28:772-80
90. Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol 2008;65:78-86
91. Kirchheiner J, Thomas S, Bauer S, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006;80:657-67
92. Tornio A, Niemi M, Neuvonen PJ, et al. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008;36:73-80
93. Zhou K, Burch L, Vella S et al. CYP2C8 variants reduce the therapeutic response to thiazolidinediones-a godarts study. Diabetologia 2010;(53 Suppl 1):S133
94. Deng LJ, Wang F, Li HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005;61:831-6
95. Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007;46:1-12
96. Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 2004;76:239-49
97. Park JY, et al. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. B J Clin Pharmacol 2004;58:397-402
98. Tornio A, Niemi M, Neuvonen PJ, et al. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008;36:73-80
99. Aquilante CL, Kosmiski LA, Bourne DW, et al. Impact of the CYP2C8*3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol 2012;doi:10.1111/j.1365-2125.2012.04343.x; [Epub ahead of print]
100. Jaakkola T, Backman JT, Neuvonen M, et al. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006;61:70-8
101. Park JY, Kim KA, Kang MH, et al. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004;75:157-62
102. Kortboyer JM, Eckland D. Pioglitazone has low potential for drug interactions. Diabetologia 1999;42(Suppl 1):A228
103. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6
104. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ. 2012;344:e1369-doi:10.1136/bmj.e1369
105. Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049-58
106. Schwarz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipepdidyl pepdidase-4 inhibitors. Am J Geriatr Pharmacother 2010;8:405-18
107. Scheen AJ. Pharmacokinetics of dipepdidylpepdidase-4 inhibitors Diabetes Obes Metab. 2010;12:648-58
108. Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27S3:57-64
109. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012;379:1403-11
110. Friedrich C, Ring A, Brand T, et al. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healty volunteers. Eur J Drug Metab Pharmacokinet 2011;36:17-24
111. Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:357-65
112. Appel S, Rufenacht T, Kalafsky G, et al. Lack of interaction between fluvastatin and oral hypoglycaemic agents in healthy subjects and in patients with non-insulindependent diabetes mellitus. Am J Cardiol 1995;76:29A-32A
113. Lilja JJ, Niemi M, Fredrikson H, et al. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 2007;63:732-40
114. Semple CG, Omile C, Buchanan KD, et al. Effect of oral verapamil on glibenclamide stimulated insulin secretion. Br J Clin Pharmacol 1986;22:187-90
115. Roberge RJ, Kaplan R, Frank R, et al. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med 2000;36:160-3
116. Lee K, Mize R, Lowenstein SR. Glyburide-induced hypoglycaemia and ranitidine. Ann Intern Med 1987;107:261-2
117. Kubacka RT, Antal EJ, Juhl RP. The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1987;23:743-51
118. Niemi M, Backman JT, Neuvonen M, et al. Effect of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001;69:194-200
119. Niemi M, Backman JT, Neuvonen M, et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001;69:400-6
120. Niemi M, Kivisto KT, Backman JT, et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. Br J Clin Pharmacol 2000;50:591-5